{"entity":{"id":"invocata","kind":"company","name":"Invocata","aka":[],"tldr":"Invocata is building personalised T-cell receptor therapies, choosing the right TCR for the individual patient at the right time; its site says only that it is coming soon.","summary":"Invocata describes personalised oncology platforms designed for the individual, moving cancer care towards an N of 1, with T-cell receptor (TCR) therapy as its route: engineering a patient's T cells to carry a receptor that recognises their own tumour. The public site is a placeholder. It is an Even One Ventures portfolio company.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://invocata.bio/"},{"label":"Even One Ventures portfolio","url":"https://evenone.ventures/"}],"tags":["startup","evenone-portfolio","oncology"],"related":[],"cancers":[],"sections":[],"technologies":["tcr-t"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"hq":"United States (head office not published)","country":"US","companyType":"cell-therapy","website":"https://invocata.bio/","stage":"startup","investors":["evenone-ventures"],"funding":[]},"route":"/companies/invocata/","neighbours":{"technology":[{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/"}],"company":[{"id":"evenone-ventures","kind":"company","name":"Even One Ventures","route":"/companies/evenone-ventures/"}]}}